Advertisement

Description of Turner Syndrome

  • Alissa J. RobertsEmail author
  • Patricia Y. Fechner
Chapter
  • 33 Downloads

Abstract

Turner syndrome describes females who have partial or complete absence of the second sex chromosome and can present with a variety of phenotypic and genotypic features. This chapter serves to summarize many of these features as well as provide an overview of clinical management guidelines. Incidence and karyotype findings are discussed prior to an overview of phenotype, commenting on skeletal manifestations, ovarian failure, cardiovascular and heart disease, lymphatic obstruction, renal abnormalities, autoimmune diseases, psychological and cognitive implications, and malignancy risk. Many of the topics introduced in this chapter will be described in further detail in subsequent chapters.

Keywords

Turner syndrome Karyotype Monosomy X 

References

  1. 1.
    Bondy CA, Turner Syndrome Study G. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007;92(1):10–25.PubMedCrossRefGoogle Scholar
  2. 2.
    Gravholt CH, Andersen NH, Conway GS, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017;177(3):G1–G70.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Nielsen J, Wohlert M. Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Hum Genet. 1991;87(1):81–3.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Gunther DF, Eugster E, Zagar AJ, Bryant CG, Davenport ML, Quigley CA. Ascertainment bias in Turner syndrome: new insights from girls who were diagnosed incidentally in prenatal life. Pediatrics. 2004;114(3):640–4.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Kagan KO, Hoopmann M, Singer S, Schaeferhoff K, Dufke A, Mau-Holzmann UA. Discordance between ultrasound and cell free DNA screening for monosomy X. Arch Gynecol Obstet. 2016;294(2):219–24.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Savendahl L, Davenport ML. Delayed diagnoses of Turner’s syndrome: proposed guidelines for change. J Pediatr. 2000;137(4):455–9.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Spatz A, Borg C, Feunteun J. X-chromosome genetics and human cancer. Nat Rev Cancer. 2004;4(8):617–29.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Davenport ML. Approach to the patient with Turner syndrome. J Clin Endocrinol Metab. 2010;95(4):1487–95.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Matsumoto F, Shimada K, Ida S. Tumors of bilateral streak gonads in patients with disorders of sex development containing y chromosome material. Clin Pediatr Endocrinol. 2014;23(3):93–7.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Tam YH, Wong YS, Pang KK, et al. Tumor risk of children with 45,X/46,XY gonadal dysgenesis in relation to their clinical presentations: Further insights into the gonadal management. J Pediatr Surg. 2016;51(9):1462–6.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Coyle D, Kutasy B, Han Suyin K, et al. Gonadoblastoma in patients with 45,X/46,XY mosaicism: a 16-year experience. J Pediatr Urol. 2016;12(5):283.e1–7.CrossRefGoogle Scholar
  12. 12.
    Flannigan RK, Chow V, Ma S, Yuzpe A. 45,X/46,XY mixed gonadal dysgenesis: a case of successful sperm extraction. Can Urol Assoc J. 2014;8(1–2):E108–10.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Landin-Wilhelmsen K, Bryman I, Hanson C, Hanson L. Spontaneous pregnancies in a Turner syndrome woman with Y-chromosome mosaicism. J Assist Reprod Genet. 2004;21(6):229–30.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Kuntsi J, Skuse D, Elgar K, Morris E, Turner C. Ring-X chromosomes: their cognitive and behavioural phenotype. Ann Hum Genet. 2000;64(Pt 4):295–305.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Fukami M, Seki A, Ogata T. SHOX haploinsufficiency as a cause of syndromic and nonsyndromic short stature. Mol Syndromol. 2016;7(1):3–11.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Malaquias AC, Scalco RC, Fontenele EG, et al. The sitting height/height ratio for age in healthy and short individuals and its potential role in selecting short children for SHOX analysis. Horm Res Paediatr. 2013;80(6):449–56.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Huguet S, Leheup B, Aslan M, et al. Radiological and clinical analysis of Madelung’s deformity in children. Orthop Traumatol Surg Res. 2014;100(6 Suppl):S349–52.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Davenport ML, Crowe BJ, Travers SH, et al. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab. 2007;92(9):3406–16.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Bondy CA, Van PL, Bakalov VK, Ho VB. Growth hormone treatment and aortic dimensions in Turner syndrome. J Clin Endocrinol Metab. 2006;91(5):1785–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Davenport ML, Roush J, Liu C, et al. Growth hormone treatment does not affect incidences of middle ear disease or hearing loss in infants and toddlers with Turner syndrome. Horm Res Paediatr. 2010;74(1):23–32.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Irzyniec TJ, Jez W. The influence of hormonal replacement and growth hormone treatment on the lipids in Turner syndrome. Gynecol Endocrinol. 2014;30(3):250–3.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Bannink EM, van der Palen RL, Mulder PG, de Muinck Keizer-Schrama SM. Long-term follow-up of GH-treated girls with Turner syndrome: BMI, blood pressure, body proportions. Horm Res. 2009;71(6):336–42.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Bakalov VK, Van PL, Baron J, Reynolds JC, Bondy CA. Growth hormone therapy and bone mineral density in Turner syndrome. J Clin Endocrinol Metab. 2004;89(10):4886–9.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Hovatta O. Ovarian function and in vitro fertilization (IVF) in Turner syndrome. Pediatr Endocrinol Rev. 2012;9(Suppl 2):713–7.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Pasquino AM, Passeri F, Pucarelli I, Segni M, Municchi G. Spontaneous pubertal development in Turner’s syndrome. Italian Study Group for Turner’s Syndrome. J Clin Endocrinol Metab. 1997;82(6):1810–3.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Bernard V, Donadille B, Zenaty D, et al. Spontaneous fertility and pregnancy outcomes amongst 480 women with Turner syndrome. Hum Reprod. 2016;31(4):782–8.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Ross JL, Roeltgen D, Feuillan P, Kushner H, Cutler GB Jr. Effects of estrogen on nonverbal processing speed and motor function in girls with Turner’s syndrome. J Clin Endocrinol Metab. 1998;83(9):3198–204.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Quigley CA, Wan X, Garg S, Kowal K, Cutler GB Jr, Ross JL. Effects of low-dose estrogen replacement during childhood on pubertal development and gonadotropin concentrations in patients with Turner syndrome: results of a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014;99(9):E1754–64.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Oktay K, Bedoschi G, Berkowitz K, et al. Fertility preservation in women with Turner syndrome: a comprehensive review and practical guidelines. J Pediatr Adolesc Gynecol. 2015;29(5):409–16.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Practice Committee of American Society For Reproductive M. Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome. Fertil Steril. 2012;97(2):282–4.Google Scholar
  31. 31.
    Mazzanti L, Cacciari E. Congenital heart disease in patients with Turner’s syndrome. Italian Study Group for Turner Syndrome (ISGTS). J Pediatr. 1998;133(5):688–92.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Gotzsche CO, Krag-Olsen B, Nielsen J, Sorensen KE, Kristensen BO. Prevalence of cardiovascular malformations and association with karyotypes in Turner’s syndrome. Arch Dis Child. 1994;71(5):433–6.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Berdahl LD, Wenstrom KD, Hanson JW. Web neck anomaly and its association with congenital heart disease. Am J Med Genet. 1995;56(3):304–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Loscalzo ML, Van PL, Ho VB, et al. Association between fetal lymphedema and congenital cardiovascular defects in Turner syndrome. Pediatrics. 2005;115(3):732–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Gravholt CH, Landin-Wilhelmsen K, Stochholm K, et al. Clinical and epidemiological description of aortic dissection in Turner’s syndrome. Cardiol Young. 2006;16(5):430–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Bondy CA. Aortic dissection in Turner syndrome. Curr Opin Cardiol. 2008;23(6):519–26.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Los E, Quezada E, Chen Z, Lapidus J, Silberbach M. Pilot study of blood pressure in girls with Turner syndrome: an awareness gap, clinical associations, and new hypotheses. Hypertension. 2016;68:133.PubMedCrossRefGoogle Scholar
  38. 38.
    Elsheikh M, Casadei B, Conway GS, Wass JA. Hypertension is a major risk factor for aortic root dilatation in women with Turner’s syndrome. Clin Endocrinol. 2001;54(1):69–73.CrossRefGoogle Scholar
  39. 39.
    Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA, United Kingdom Clinical Cytogenetics G. Mortality in women with turner syndrome in Great Britain: a national cohort study. J Clin Endocrinol Metab. 2008;93(12):4735–42.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Mavinkurve M, O’Gorman CS. Cardiometabolic and vascular risks in young and adolescent girls with Turner syndrome. BBA Clin. 2015;3:304–9.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Bilge I, Kayserili H, Emre S, et al. Frequency of renal malformations in Turner syndrome: analysis of 82 Turkish children. Pediatr Nephrol. 2000;14(12):1111–4.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Livadas S, Xekouki P, Fouka F, et al. Prevalence of thyroid dysfunction in Turner’s syndrome: a long-term follow-up study and brief literature review. Thyroid. 2005;15(9):1061–6.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Bonamico M, Pasquino AM, Mariani P, et al. Prevalence and clinical picture of celiac disease in Turner syndrome. J Clin Endocrinol Metab. 2002;87(12):5495–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005;40(1):1–19.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Jorgensen KT, Rostgaard K, Bache I, et al. Autoimmune diseases in women with Turner’s syndrome. Arthritis Rheum. 2010;62(3):658–66.PubMedCrossRefGoogle Scholar
  46. 46.
    Ross J, Zinn A, McCauley E. Neurodevelopmental and psychosocial aspects of Turner syndrome. Ment Retard Dev Disabil Res Rev. 2000;6(2):135–41.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    McCauley E, Feuillan P, Kushner H, Ross JL. Psychosocial development in adolescents with Turner syndrome. J Dev Behav Pediatr. 2001;22(6):360–5.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Ji J, Zoller B, Sundquist J, Sundquist K. Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: a national cohort study. Int J Cancer. 2016;139(4):754–8.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA, Group UKCC. Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study. Lancet Oncol. 2008;9(3):239–46.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Hasle H, Olsen JH, Nielsen J, Hansen J, Friedrich U, Tommerup N. Occurrence of cancer in women with Turner syndrome. Br J Cancer. 1996;73(9):1156–9.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Larizza D, Albanesi M, De Silvestri A, et al. Neoplasia in Turner syndrome. The importance of clinical and screening practices during follow-up. Eur J Med Genet. 2016;59(5):269–73.PubMedCrossRefGoogle Scholar
  52. 52.
    Bell J, Parker KI, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95(2):167–77.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Bolar K, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormonein Turner syndrome. J Clin Endocrinol Metab. 2008;93(1):344–51.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Child CJ, Zimmermann AG, Chrousos GP, et al. Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program. J Clin Endocrinol Metab. 2019;104(2):379–89.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Pier DB, Nunes FP, Plotkin SR, et al. Turner syndrome and meningioma: support for a possible increased risk of neoplasia in Turner syndrome. Eur J Med Genet. 2014;57(6):269–74.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Alexiou GA, Varela M, Dimitriadis E, et al. Brain tumors in Turner syndrome. Eur J Med Genet. 2014;57(6):312–3.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of EndocrinologySeattle Children’s Hospital, University of WashingtonSeattleUSA

Personalised recommendations